Clinical Effectiveness of Liraglutide Across Body Mass Index in Patients with Type 2 Diabetes in the United States: A Retrospective Cohort Study

Introduction Clinical trials have shown that liraglutide effectively lowers glycated hemoglobin A1c (A1C) levels in adult patients with type 2 diabetes (T2D). However, no studies have evaluated the effectiveness of liraglutide by body mass index (BMI) in the United States (US) in clinical practice....

Full description

Saved in:
Bibliographic Details
Published in:Advances in therapy 2014-09, Vol.31 (9), p.986-999
Main Authors: Chitnis, Abhishek S., Ganz, Michael L., Benjamin, Nicole, Langer, Jakob, Hammer, Mette
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Biological and medical sciences
Body Mass Index
Body Weight
Cardiology
Diabetes Mellitus, Type 2 - drug therapy
Diabetes. Impaired glucose tolerance
Endocrine pancreas. Apud cells (diseases)
Endocrinology
Endocrinopathies
Etiopathogenesis. Screening. Investigations. Target tissue resistance
Female
Glycated Hemoglobin A - analysis
Humans
Hypoglycemia
Hypoglycemic Agents - therapeutic use
Internal Medicine
Liraglutide - therapeutic use
Male
Medical sciences
Medicine
Medicine & Public Health
Middle Aged
Oncology
Original Research
Pharmacology. Drug treatments
Pharmacology/Toxicology
Retrospective Studies
Rheumatology
United States
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Clinical trials have shown that liraglutide effectively lowers glycated hemoglobin A1c (A1C) levels in adult patients with type 2 diabetes (T2D). However, no studies have evaluated the effectiveness of liraglutide by body mass index (BMI) in the United States (US) in clinical practice. This study examined liraglutide’s clinical effectiveness to lower A1C and body weight after 6 months in T2D patients stratified by baseline BMI. Methods This was a retrospective cohort study using the General Electric Centricity electronic medical records database. Adult patients with T2D (≥18 years and BMI≥ 25 kg/m 2 ) and A1C >7% at baseline who started liraglutide between January 1, 2010 and January 31, 2013 and who did not use insulin or a glucagon-like peptide-1 analog 12 months before initiating liraglutide ( N  = 3,005) were selected. Changes from baseline, stratified by BMI, in A1C, body weight, A1C
ISSN:0741-238X
1865-8652
DOI:10.1007/s12325-014-0153-5